DexCare, whose software helps health systems manage capacity and patient appointment booking, raises a $50M Series B, after a $20M round in March 2021
Context & Ripple Effects
DexCare's $50M Series B lands in the middle of a funding run on healthcare scheduling software: Solv raised a $45M Series C for same-day appointment booking in September 2021, and NexHealth started with a $15M Series A in 2020 before scaling to a $125M Series C at a $1B valuation by April 2022. DexCare's own trajectory — $20M in March 2021 to $50M now — tracks that curve.
What distinguishes DexCare within the cluster is its customer: capacity management and appointment booking sold to entire health systems, rather than the small-practice focus of NexHealth's early product or Solv's consumer-facing same-day slotting.
First-order effects
- DexCare gains roughly 2.5x its previous round in new capital to push its capacity-and-booking software into more health-system deployments, where long procurement cycles make runway the binding constraint.
- Health systems evaluating scheduling vendors now see a funded specialist whose pitch spans both operational capacity and patient-facing booking, not just one side.
Second-order effects
- Solv and NexHealth face a better-capitalized rival attacking the enterprise end of the market, pressuring them to either move upmarket toward health systems or defend their existing segments — Solv's provider-side booking, NexHealth's EHR-integrated real-time scheduling.
- EHR vendors and health-system IT buyers gain leverage as scheduling startups compete on integration depth, since whoever owns the EHR connection controls the data flow that makes automated booking work.
Third-order effects
- If the pattern holds, patient scheduling consolidates into an EHR-integrated infrastructure layer dominated by a few well-funded platforms, squeezing out point solutions that serve single practices without system-wide capacity data.
- Capital concentration in this segment suggests health systems will increasingly treat digital patient access as core purchased infrastructure rather than a marketing add-on, reshaping how appointment supply is allocated across networks.
The trend: Venture capital is consolidating around EHR-integrated scheduling platforms as health systems digitize patient access, with round sizes escalating rapidly across the category.